Alnylam just won the ATTR-CM narrative, and the market still may not be fully pricing how important that is. AstraZeneca and Ionis reported that Wainua missed the primary endpoint in Phase 3 ATTR-CM, while Alnylam already has AMVUTTRA approved in the indication and scaling commercially. That matters because this is no longer a story about a promising platform waiting for proof; it is a story about an approved franchise gaining ground as a major rival stumbles. For a biotech trading at 9.8 times sales with 65.2% revenue growth and positive earnings, that setup still looks more attractive than fully crowded skepticism suggests.
The cleanest bull point is competitive positioning. Wainua failed to reduce the composite of cardiovascular mortality and recurrent cardiovascular clinical events in its late-stage ATTR-CM study, and that immediately made AMVUTTRA look more entrenched as the RNAi standard in the space. Alnylam is not trying to win this market on theory anymore; AMVUTTRA already carries the U.S. ATTR-CM label, and that first-mover commercial advantage gets stronger when one of the most credible challengers falls out of the lane.
The second point is that the business was already inflecting before this read-through. Alnylam crossed $1 billion in quarterly product revenue for the first time in Q1 2026, with management tying that performance mainly to AMVUTTRA demand in U.S. ATTR-CM patients. At the company level, revenue is now $3.71 billion, up 65.2% year over year, while EPS growth is running at 209.6% and net income growth at 212.8%. That is exactly the profile investors want after a competitive shakeout: not a pre-revenue hope trade, but a company already converting clinical leadership into real sales and real earnings.
The quality of that growth also stands out. Gross margin is 80.9%, operating margin is 17.5%, and net margin is 13.5%, which is why the Profitability component of the TickerSpark Score sits at 95 and the Growth component is a perfect 100. Even valuation looks more reasonable than biotech skeptics may assume. ALNY trades at 9.8 times sales, well below ARGX at 16.51 times sales, despite posting a much faster growth profile than most large-cap healthcare names and now owning one of the strongest competitive narratives in rare disease cardiology.
The obvious pushback is that one rival miss does not create a monopoly. BridgeBio remains a live competitor in ATTR-CM, and Wainua's failure came in a trial where 57% of patients were already on a stabilizer at baseline and another 24% started one during the study, so bulls cannot pretend every commercial question is settled. ALNY also is not cheap on traditional earnings metrics, with a 72.17 P/E and 44.97 EV/EBITDA, and the stock is still down 21.2% year to date while underperforming healthcare by 25.7 percentage points.
Those are real issues, but they do not break the thesis. They actually explain why the opportunity still exists. The market is treating Alnylam like a stock that still needs to prove durability, even as the company posts triple-digit EPS growth, positive net income, and a major competitive win in its most important growth market. That disconnect is exactly why this setup remains compelling rather than crowded.
What we'd do here is stay constructive and use the next earnings print as the check on whether the market has fully caught up. Alnylam has beaten earnings in five of the last seven reported quarters, and the July 30 report is the next chance for AMVUTTRA uptake to confirm that the post-Wainua read-through is translating into harder numbers. If product revenue momentum stays anywhere near the pace implied by that first $1 billion quarter, the bull case remains intact.
The risk is not that the story lacks momentum; it is that expectations can run ahead of execution after a headline win. That keeps this in the category of a high-quality biotech growth position rather than a table-pounding oversized bet. Still, with an Overall TickerSpark Score of 75, elite profitability and growth sub-scores, and a competitive field that just got narrower, we'd rather own ALNY than chase less-proven biotech narratives right now.
